FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: FendX Technologies Inc. (the "Issuer").

Trading Symbol: FNDX

Number of Outstanding Listed Securities: 9,340,161 (as at April 30, 2026)

Date: May 1, 2026

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

(a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.

(b) The term "Issuer" includes the Issuer and any of its subsidiaries.

(c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

   During the month of April, the Issuer continued its research and development and scale-up activities on its nanotechnology products in development . The Issuer is continuing its work on its liquid surface coating (formerly referred to as the spray coating) where the Issuer has conducted antimicrobial testing with a third party lab and signed a statement of work

with contract manufacturer to commence pilot scale-up work to create larger batch sizes of the liquid surface coating for further testing as well as to assess the manufacturing process. The Issuer also continued its development collaboration with McMaster University (“McMaster”) on the Issuer’s Foley catheter coating and in April 2026, the Issuer engaged a third party to conduct a US U.S. Food and Drug Administration (“FDA”) regulatory pathway assessment for this Foley catheter coating product under development.

2. Provide a general overview and discussion of the activities of management.

During April, management focused on continuing oversight of its research and development activities being conducted at McMaster to advance its Foley catheter project and engaged a third party contract manufacturer to commence pilot scale-up of its liquid surface coating to create larger batch sizes for further testing. Management was successful in engaging a third party consultant to conduct an FDA regulatory pathway assessment for its Foley Catheter Coating product under development.

Management continues to focus on pursuing business development opportunities involving other technologies and/or products to complement the Issuer’s current portfolio. During April, management also continued working with a third-party to develop the underlying detection methods and supporting data related to a microbial detection app. The Issuer is also preparing to engage a software developer to build the application.

Management also attended to administrative matters, business development, and general management, including filing of the Issuer’s audited annual financial statements. Additionally, management completed debt settlement transactions with three third party consultants aggregating $89,578 settled through the issuance of 242,102 shares. The Issuer holds regular management meetings regarding its business plan and executes action items that result from these meetings.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

N/A

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

N/A

5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

On April 15, 2026, the Issuer announced the signing of a statement of work with Galenvs Sciences Inc., a third party contract manufacturer, to initiate pilot scale manufacturing work on the Issuer's Liquid Surface Coating product under development. On April 29, 2026, the Issuer announced the engagement of Innovotech Labs Corp., a third party technology company, to conduct an FDA regulatory assessment for the Issuer's Foley Catheter Coating product under development.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

   In April 2026 Aquaox LLC notified the Company it could not achieve the feasibility requirements thus terminating the January 20, 2026 collaboration agreement. Because this phase was foundational to the broader product development outlined in the MOU signed in November 2025, on April 14, 2026 the Issuer provided 30 day notice to Aquaox to terminate the MOU.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

   N/A

8. Describe the acquisition of new customers or loss of customers.

   N/A

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

   N/A

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

    N/A

11. Report on any labour disputes and resolutions of those disputes if applicable.

    N/A

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

    N/A

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

During April 2026, the Issuer received a loan of $50,000 from an associate of a Related Party and received a loan of $10,000 from a Related Party. The loans are non-interest bearing and have no fixed term of repayment.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds
Common Shares	242,102	Common shares issued on April 10, 2026 pursuant to share for debt transactions with three creditors at a deemed price of $0.37 per share.	N/A

15. Provide details of any loans to or by Related Persons.

See item 13.

16. Provide details of any changes in directors, officers or committee members.

N/A

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The recent emergence of global health threats, including the COVID-19 pandemic, a highly virulent variant of Mpox, interspecies transmission of avian influenza, and the rise of drug-resistant bacteria, highlights the importance of controlling the spread of pathogens. Many pathogens can spread via surfaces, posing potential public health risks. Global health authorities, like the CDC and WHO, are focused on developing strategies and recommendations to reduce pathogen transmission. The Issuer believes its surface protection products in development may contribute to the broader effort to mitigate pathogen transmission.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 7 Monthly Progress Report is true.

Dated May 1, 2026

Carolyn Myers
Name of Director or Senior Officer

"Carolyn Myers"
Signature

CEO and Director
Official Capacity

Issuer Details Name of Issuer FendX Technologies Inc.	For Month End April 30, 2026	Date of Report YY/MM/DD 26/05/01
Issuer Address 701 West Georgia Street, Suite 1500		
City/Province/Postal Code Vancouver, BC, V7Y 1C6	Issuer Fax No. ( )	Issuer Telephone No. (800) 344-9868
Contact Name Carolyn Myers	Contact Position CEO	Contact Telephone No. (800) 344-9868
Contact Email Address carolyn@fendxtech.com	Web Site Address www.fendxtech.com	